ESGE and ESGENA comment: Duodenoscope design

ESGE and ESGENA recently issued a statement pertaining to the use of removable caps on duodenoscopes: You may be aware of the recent debate regarding the suggestions by some regulatory authorities (e.g. the US Food and Drug Administration [FDA]) of the need to use removable caps (reusable or single use) on duodenoscopes, and furthermore advocating the development of fully disposable ...

Read More »

Cannabinoid compounds may inhibit growth of colon cancer cells

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine researchers say some cannabinoid compounds may actually inhibit the growth of colon cancer cells in the lab. The researchers tested the effects of synthetic cannabinoid compounds on colon cancer cells in an experiment in test ...

Read More »

Study reveals how mucus tames microbes

More than 200 square meters of our bodies — including the digestive tract, lungs, and urinary tract — are lined with mucus. In recent years, scientists have found some evidence that mucus is not just a physical barrier that traps bacteria and viruses, but it can also disarm pathogens and prevent them from causing infections. A new study from MIT ...

Read More »

Crohn’s & Colitis Foundation selected for FDA MyStudies app project

The Crohn’s & Colitis Foundation was selected as one of two patient organizations to participate in an U.S. Food & Drug Administration (FDA) Real-World Evidence Program demonstration project using the FDA MyStudies App through the FDA-Catalyst system. The FDA Real World Evidence Program will inform the assessment of the fitness for use of real-world data to support real-world evidence generation for ...

Read More »

Crohn’s disease study identifies genetic variant with potential to personalize treatment

The largest study ever to look at why an expensive and commonly–used group of drugs fails some patients with Crohn’s disease has identified a genetic marker which could individualize drug treatment. A UK wide collaboration led by the University of Exeter, Royal Devon & Exeter NHS Foundation Trust and the Wellcome Sanger Institute, has demonstrated that a genetic variant carried by 40% of the ...

Read More »